Registration Dossier

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Toxic effect type:
dose-dependent

Effects on fertility

Description of key information

No Observed Adverse Effect Level (NOAEL) for reproductive toxicity was considered to be 1000 mg/kg/day, as no effects on reproductive organ weight and histopathology, when male and female Sprague Dawley rats were treated with test chemical orally for 90 days.

Link to relevant study records
Reference
Endpoint:
reproductive toxicity, other
Remarks:
sub chronic toxicity study
Type of information:
experimental study
Adequacy of study:
weight of evidence
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
secondary literature
Justification for type of information:
Data from secondary source
Qualifier:
equivalent or similar to guideline
Guideline:
other: OECD guideline 408
Principles of method if other than guideline:
Reproductive toxicity study of test material was performed on Sprague Dawley rats
GLP compliance:
not specified
Limit test:
no
Justification for study design:
No data available
Species:
rat
Strain:
Sprague-Dawley
Remarks:
Crl: CD(SD)BR)
Details on species / strain selection:
No data available
Sex:
male/female
Details on test animals or test system and environmental conditions:
- Age: 5/6 weeks
- Weight at study initiation: male : 115-174 g, female : 97-150 g
Route of administration:
oral: gavage
Vehicle:
water
Remarks:
distilled water
Details on exposure:
Details on exposure
PREPARATION OF DOSING SOLUTIONS:Test material soluble in distilled water
DIET PREPARATION- Rate of preparation of diet (frequency):
- Mixing appropriate amounts with (Type of food):
- Storage temperature of food:
VEHICLE
- Justification for use and choice of vehicle (if other than water):
- Concentration in vehicle: 0, 250, 500, 1000 mg /kg-
Amount of vehicle (if gavage):10ml /kg bw
- Lot/batch no. (if required):
- Purity:
Analytical verification of doses or concentrations:
not specified
Duration of treatment / exposure:
90 days
Frequency of treatment:
5 days/week
Details on study schedule:
No data available
Remarks:
0, 250, 500, 1000 mg /kg
No. of animals per sex per dose:
Total:800 mg/kg :
10 male and 10 female 250mg/kg:
10 male and 10 female: 500mg/kg
10 male and 10 female: 1000 mg/kg:
10 male and 10 female: 0 mg/kg
Control animals:
yes, concurrent vehicle
Details on study design:
No data available
Positive control:
No data available
Parental animals: Observations and examinations:
Parental animals observation and examinations
CAGE SIDE OBSERVATIONS: yes
DETAILED CLINICAL OBSERVATIONS: Yes
Time schedule: daily
BODY WEIGHT: Yes

Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes twice/week
Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data: No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
Time schedule for examinations:
OTHER:
Oestrous cyclicity (parental animals):
No data available
Sperm parameters (parental animals):
No data available
Litter observations:
No data available
Postmortem examinations (parental animals):
Postmortem examinations (Parent Animal)
SACRIFICE :On day 92
GROSS NECROPSY: yes
HISTOPATHOLOGY / ORGAN WEIGHTS : yes
Postmortem examinations (offspring):
No data available
Statistics:
Levene´s test (body weight, body weight gain, food consumption), ANOVA, Dunnett´s test (both for multiple group comparisons), Student-Newman-Keul (organ weight, chlinical chemistry, hematology data organ/body weight ratio with each one factor treatment)
Reproductive indices:
No data available
Offspring viability indices:
No data available
Clinical signs:
no effects observed
Description (incidence and severity):
No treatment-related clinical signs were observed
Dermal irritation (if dermal study):
no effects observed
Mortality:
no mortality observed
Description (incidence):
There were no treatment-related mortalities
Body weight and weight changes:
not specified
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
no effects observed
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
No treatment related effects on histopathology of testes, accessory sex organs, ovaries, uterus, prostate
Histopathological findings: neoplastic:
not specified
Other effects:
not specified
Reproductive function: oestrous cycle:
not specified
Reproductive function: sperm measures:
not specified
Reproductive performance:
not specified
Dose descriptor:
NOAEL
Effect level:
1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
clinical signs
mortality
organ weights and organ / body weight ratios
histopathology: non-neoplastic
Remarks on result:
other: No effects on reproductive organ
Critical effects observed:
not specified
System:
other: not specified
Organ:
not specified
Clinical signs:
not specified
Dermal irritation (if dermal study):
not specified
Mortality / viability:
not specified
Body weight and weight changes:
not specified
Food consumption and compound intake (if feeding study):
not specified
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Sexual maturation:
not specified
Organ weight findings including organ / body weight ratios:
not specified
Gross pathological findings:
not specified
Histopathological findings:
not specified
Other effects:
not specified
Behaviour (functional findings):
not specified
Developmental immunotoxicity:
not specified
Dose descriptor:
other: not specified
Generation:
other: not specified
Based on:
not specified
Sex:
not specified
Basis for effect level:
other: not specified
Remarks on result:
not measured/tested
Critical effects observed:
not specified
System:
other: not specified
Organ:
not specified
Reproductive effects observed:
not specified
Treatment related:
not specified
Conclusions:
No Observed Adverse Effect Level (NOAEL) for reproductive toxicity was considered to be 1000 mg/kg/day, as no effects on reproductive organ weight and histopathology, When male and female Sprague Dawley rats were treated with test chemical orally for 90 days.
Executive summary:
A 90 days subchronic toxicity study of test chemical was performed according to OECD TG 408 on male and female Sprague-Dawley rats. The test material was dissolved in distilled water at dose levels of 0, 250, 500 or 1000 mg/kg-day and administered via oral gavage route once a day for 5 days/week in dose volume 10ml/kg bw in Sprague-Dawley rats 10/sex/dose was used in the study. All the animals were observed for Clinical signs and mortality daily. Body weight and food consumption were noted twice a week. On day 92, all the animals were sacrificed and Gross pathology and Histopathology were performed. There were no treatment-related mortalities in any test group. No effects on Body weight and food consumption were noted. No effects on testes and ovaries weights were noted. No treatment related effects on histopathology of testes, accessory sex organs, ovaries, uterus and prostate were noted. Hence No Observed Adverse Effect Level (NOAEL) for reproductive toxicity was considered to be 1000 mg/kg/day, as no effects on reproductive organ weight and histopathology were observed, when male and female Sprague Dawley rats were treated with test chemical orally for 90 days.
Effect on fertility: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
1 000 mg/kg bw/day
Study duration:
subchronic
Species:
rat
Quality of whole database:
Data is Klimicsh 2 and from authoritative database
Effect on fertility: via inhalation route
Endpoint conclusion:
no study available
Effect on fertility: via dermal route
Endpoint conclusion:
no study available
Additional information

Data available for the read across chemicals was reviewed to determine the reproductive toxicity of test chemical. The studies are as mentioned below:

Study 1: A 90 days subchronic toxicity study of test chemical was performed according to OECD TG 408 on male and female Sprague-Dawley rats. The test material was dissolved in distilled water at dose levels of 0, 250, 500 or 1000 mg/kg-day and administered via oral gavage route once a day for 5 days/week in dose volume 10ml/kg bw in Sprague-Dawley rats 10/sex/dose was used in the study. All the animals were observed for Clinical signs and mortality daily. Body weight and food consumption were noted twice a week. On day 92, all the animals were sacrificed and Gross pathology and Histopathology were performed. There were no treatment-related mortalities in any test group. No effects on Body weight and food consumption were noted. No effects on testes and ovaries weights were noted. No treatment related effects on histopathology of testes, accessory sex organs, ovaries, uterus and prostate were noted. Hence No Observed Adverse Effect Level (NOAEL) for reproductive toxicity was considered to be 1000 mg/kg/day, as no effects on reproductive organ weight and histopathology were observed, when male and female Sprague Dawley rats were treated with test chemical orally for 90 days.

 

Study 2: The prenatal developmental toxicity study following OECD guideline 414 was performed on female CD rats. Test material was soluble in water (aqua ad iniectabilia). Dose concentration were prepared at 0, 330, 990 or 3300 mg/kg-day (corresponding to 0, 95, 286, and 950 mg/kg-day active substance, respectively) and administered in a dose volume of 10 ml/kg bw from day 5 to 19 of pregnancy once daily via gavage. 25 female rats /dose group were treated and 20 pregnant animals were evaluated. 20 rats (0, 330, 990 mg/kg bw group) and 21 rats (3300 mg/kg bw group) were evaluated for maternal toxicity. 1 male and 1 female were placed in one cage during the dark period. Mating was repeated until vaginal smear showed presence of sperm. All animals were observed for clinical signs, Body weight and food consumption daily. Also number of fetuses alive, Weight of fetuses, sex distribution of fetuses, skeletal anomalies (50 %) and soft tissue anomalies (50 %) were noted. One dam at 3300 mg/kg day died on gestation day 15 and in same dose group 13/21 abdominal position, 2/21: pilo-erection, reduced motility was noted. At≥990 mg/kg bw dose group, reduction of the net weight change (carcass weight minus day 6 body weight) from day 6 onwards (23% and 67%) and reduced food consumption (up to 12 % gestation days 8, 10, 19), 4/20: ulcers, thickened mucosa were observed. At 3300 mg/kg bw dose group, reduced body weight (up to 17 % below control) and decreased body weight change, reduced food consumption up to 65% each day, reduced gravid uterus weight by 22% (caused by lowered fetal weights) and 20/21: thickened mucosa, greyish discolored in 2/21; ulcers (also in the prematurely deceased dam) were observed. The number of early, late and total resorptions was increased in the 3300 mg/kg bw group. Moreover the ratio of viable fetuses to implantation sites was decreased compared to the controls. This was due to a total post-implantation loss of two dams in this dose group. A statistically significant reduction in fetal weights and number of viable fetuses as compared to the control was observed. At 3300 mg/kg bw dose group. No external, skeletal or soft tissue malformations and no external variations were seen in controls or in dosed groups. The fetal incidence of the skeletal variations was 5 in the controls and 8 (330 mg/kg bw), 13 (990 mg/kg bw) and 6 (3300 mg/kg bw) in the test group respectively. The finding in the 990 mg/kg bw group was judged as incidental as no dose-relationship was noted. The skeletal retardations (fetal incidence) were 129 in the controls and 137 (330 mg/kg bw), 130 (990 mg/kg bw) and 125 (3300 mg/kg bw) in the dosed groups. No dose-related soft tissue variations were observed, as seen in the following fetal incidences: 8 (control), 12 (330 mg/kg bw), 10 (990 mg/kg bw) and 9 (3300 mg/kg bw). Hence, the NOAEL for maternal toxicity was 95 mg/kg bw/day and the NOAEL for reproductive and developmental toxicity was >950 mg/kg bw/day as the post-implantation loss and decreased mean fetal body weight were considered to be secondary to maternal toxicity when female CD rats were treated with test chemical orally from day 5 - 19 of pregnancy.

Study 3: In a reproductive toxicity study, Sprague-Dawley female rats were treated with test chemical in the concentration of 0, 100, 300, or 1000 mg/kg/day orally by gavage in corn oil. No maternal mortality and clinical signs or behavioral changes were observed in treated female rats as compared to control. No effect on body weight and feed consumption changes were observed in treated female rats as compared to control. Similarly, no effect on reproductive parameters such as number of corpora lutea, number of live fetuses per litter, litter size, mean fetal body weight, or mean crown-rump length was observed in treated rats. Ratio of male and female pups at the 1000 mg/ kg/day dose level was significantly different from the control group but was not considered treatment related. Slight but significant increase in relative liver weight of treated female rats was observed as compared to control. In addition, No effect on viability, fetal body weight and external malformations were observed in treated fetuses as compared to control. One fetus with bent limb bones, two fetuses from different mothers with microphthalmia and two other fetuses with omphalocele were observed at 1000 mg/kg/day and single fetus with multiple malformations were observed at 300 mg/kg/day in treated fetuses as compared to control. The incidence of developmental variations in the treated litters was not significantly increased over the control incidence. They occurred in low frequency and were distributed randomly across the test chemical treated and control groups. Therefore, NOAEL was considered to be 300 mg/kg bw for P generation and 1000 mg/kg for F1 generation when Sprague-Dawley female rats were treated with test chemical orally by gavage from day 6 to 15 of gestation.

Based on the data available from different studies, test chemical did not showed reproductive toxicity at dose concentration between 300- 1000mg/kg bw/day. Hence the test chemical is not likely to classify as a reproductive and developmental toxicant as per the criteria mentioned in CLP regulation.

Effects on developmental toxicity

Description of key information

The NOAEL for maternal toxicity was 95 mg/kg bw/day and the NOAEL for developmental toxicity was >950 mg/kg bw/day as the post-implantation loss and decreased mean foetal body weight were considered to be secondary to maternal toxicity when female CD were treated with test chemical orally from day 5 - 19 of pregnancy.

Link to relevant study records
Reference
Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
weight of evidence
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
secondary literature
Justification for type of information:
Data from secondry source
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Principles of method if other than guideline:
Developmental toxicity study of test material was performed on female CD rats.
GLP compliance:
not specified
Limit test:
no
Species:
rat
Strain:
other: CD
Details on test animals or test system and environmental conditions:
Age at day 0 of pregnancy: 8 - 9 weeks- Body weight at day 0 of pregnancy: 205 - 254 g
Route of administration:
oral: gavage
Vehicle:
water
Remarks:
(aqua ad iniectabilia)
Details on exposure:
Details on exposure
PREPARATION OF DOSING SOLUTIONS:Test material soluble in water (aqua ad iniectabilia)

DIET PREPARATION
- Rate of preparation of diet (frequency):- Mixing appropriate amounts with (Type of food):
- Storage temperature of food:

VEHICLE
- Justification for use and choice of vehicle (if other than water):
- Concentration in vehicle: 0, 330, 990 or3300 mg/kg-day (corresponding to 0, 95, 286, and 950 mg/kg-day active substance, respectively)
- Amount of vehicle (if gavage):10ml /kg bw
- Lot/batch no. (if required)
:- Purity:
Analytical verification of doses or concentrations:
not specified
Details on mating procedure:
- Impregnation procedure: [artificial insemination / purchased timed pregnant / cohoused]
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: during the dark period.
- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: [no / yes (explain)]
- Verification of same strain and source of both sexes: [yes / no (explain)]
- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0 / day 1] of pregnancy
- Any other deviations from standard protocol:
Duration of treatment / exposure:
15 days (from day 5 - 19 of pregnancy)
Frequency of treatment:
Daily
Duration of test:
20 days
Remarks:
0, 330, 990 or 3300 mg/kg-day (corresponding to 0, 95, 286, and 950 mg/kg-day active substance, respectively)
No. of animals per sex per dose:
Total:
1000 mg/kg : 25 female
95 mg/kg:25 female
286 mg/kg:25 female
950 mg/kg:25 female
Control animals:
yes, concurrent vehicle
Details on study design:
No data available
Maternal examinations:
Parental animals observation and examinations
CAGE SIDE OBSERVATIONS: yes
DETAILED CLINICAL OBSERVATIONS: Yes
Time schedule: daily
BODY WEIGHT: Yes, Time schedule for examinations: daily
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes daily Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Compound intake calculated as time
-weighted averages from the consumption and body weight gain data: Yes / No / No data: No data available
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data Time schedule for examinations
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other:
Fetal examinations:
- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: No data
Statistics:
Postmortem examinations (Parent Animal)
SACRIFICE : on days 20
GROSS NECROPSY: yes
HISTOPATHOLOGY / ORGAN WEIGHTS : yes
Indices:
No data available
Historical control data:
No data available
Clinical signs:
no effects observed
Description (incidence and severity):
At 3300 mg/kg bw dose group 13/21 abdominal position, 2/21: pilo-erection, reduced motility
Dermal irritation (if dermal study):
not specified
Mortality:
mortality observed, treatment-related
Description (incidence):
One dam at 3300 mg/kg day died on gestation day 15
Body weight and weight changes:
effects observed, treatment-related
Description (incidence and severity):
>= 990 mg/kg bw dose group reduction of the net weight change (carcass weight minus day 6 body weight) from day 6 onwards (23% and 67%). At 3300 mg/kg bw dose group reduced body weight (up to 17 % below control) and decreased body weight change were observed
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Description (incidence and severity):
>= 990 mg/kg bw dose group reduced food consumption (up to 12 % gestation days 8, 10, 19)and at 3300 mg/kg bw dose group up to 65% each day
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not specified
Ophthalmological findings:
not specified
Haematological findings:
not specified
Clinical biochemistry findings:
not specified
Urinalysis findings:
not specified
Behaviour (functional findings):
not specified
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Description (incidence and severity):
In 3300 mg/kg bw dose group reduced gravid uterus weight by 22% (caused by lowered fetal weights)
Gross pathological findings:
effects observed, treatment-related
Description (incidence and severity):
At 990 mg/kg bw dose group 4/20: ulcers, thickened mucosa and in 3300 mg/kg bw dose group 20/21: thickened mucosa, greyish discoloured in 2/21; ulcers (also in the prematurely deceased dam) were observed.
Neuropathological findings:
not specified
Histopathological findings: non-neoplastic:
not specified
Histopathological findings: neoplastic:
not specified
Other effects:
not specified
Number of abortions:
not specified
Pre- and post-implantation loss:
effects observed, treatment-related
Description (incidence and severity):
the ratio of viable fetuses to implantation sites was decreased compared to the controls. This was due to a total post-implantation loss of two dams in the 3300 mg/kg bw dose group.
Total litter losses by resorption:
not specified
Early or late resorptions:
effects observed, treatment-related
Description (incidence and severity):
The number of early, late and total resorptions was increased in the 3300 mg/kg bw group.
Dead fetuses:
not specified
Changes in pregnancy duration:
not specified
Changes in number of pregnant:
not specified
Other effects:
not specified
Dose descriptor:
NOAEL
Effect level:
95 mg/kg bw/day (nominal)
Based on:
test mat.
Basis for effect level:
body weight and weight gain
clinical signs
food consumption and compound intake
gross pathology
mortality
organ weights and organ / body weight ratios
pre and post implantation loss
total litter losses by resorption
Remarks on result:
other: No toxic effects observed at given dose group
Abnormalities:
not specified
Localisation:
not specified
Fetal body weight changes:
effects observed, treatment-related
Description (incidence and severity):
a statistically significant reduction in fetal weights as compared to the control was observed At 3300 mg/kg bw dose group
Description (incidence and severity):
a statistically significant reduction in number of viable fetuses as compared to the control was observed At 3300 mg/kg bw dose group
Changes in sex ratio:
not specified
Changes in litter size and weights:
not specified
Changes in postnatal survival:
not specified
External malformations:
no effects observed
Description (incidence and severity):
No external malformations and no external variations were seen in controls or in dosed groups.
Skeletal malformations:
no effects observed
Description (incidence and severity):
No skeletal were seen in controls or in dosed groups.
Visceral malformations:
no effects observed
Description (incidence and severity):
No soft tissue malformations were seen in controls or in dosed groups.
Other effects:
effects observed, treatment-related
Description (incidence and severity):
The fetal incidence of the skeletal variations was 5 in the controls and 8 (330 mg/kg bw), 13 (990 mg/kg bw) and 6 (3300 mg/kg bw). The finding in the 990 mg/kg bw group was judged as incidental as no dose-relationship was noted. The skeletal retardations (fetal incidence) were 129 in the controls and 137 (330 mg/kg bw), 130 (990 mg/kg bw) and 125 (3300 mg/kg bw) in the dosed groups. No dose-related soft tissue variations were observed, as seen in the following fetal incidences: 8 (control), 12 (330 mg/kg bw), 10 (990 mg/kg bw) and 9 (3300 mg/kg bw)
Dose descriptor:
NOAEL
Effect level:
> 950 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
not specified
Basis for effect level:
reduction in number of live offspring
fetal/pup body weight changes
external malformations
skeletal malformations
visceral malformations
Remarks on result:
other: No developmental toxic effects observed
Abnormalities:
not specified
Localisation:
other: not specified
Developmental effects observed:
not specified
Treatment related:
not specified
Conclusions:
The NOAEL for maternal toxicity was 95 mg/kg bw/day and the NOAEL for developmental toxicity was >950 mg/kg bw/day as the post-implantation loss and decreased mean foetal body weight were considered to be secondary to maternal toxicity when female CD were treated with test chemical orally from day 5 - 19 of pregnancy.
Executive summary:

The prenatal developmental toxicity study following OECD guideline 414 was performed on female CD rats. Test material was soluble in water (aqua ad iniectabilia). Dose concentration were prepared at 0, 330, 990 or 3300 mg/kg-day (corresponding to 0, 95, 286, and 950 mg/kg-day active substance, respectively) and administered in a dose volume of 10 ml/kg bw from day 5 to 19 of pregnancy once daily via gavage. 25 female rats /dose group were treated and 20 pregnant animals were evaluated. 20 rats (0, 330, 990 mg/kg bw group) and 21 rats (3300 mg/kg bw group) were evaluated for maternal toxicity. 1 male and 1 female were placed in one cage during the dark period. Mating was repeated until vaginal smear showed presence of sperm. All animals were observed for clinical signs, Body weight and food consumption daily. Also number of fetuses alive, Weight of fetuses, sex distribution of fetuses, skeletal anomalies (50 %) and soft tissue anomalies (50 %) were noted. One dam at 3300 mg/kg day died on gestation day 15 and in same dose group 13/21 abdominal position, 2/21: pilo-erection, reduced motility was noted. At≥990 mg/kg bw dose group, reduction of the net weight change (carcass weight minus day 6 body weight) from day 6 onwards (23% and 67%) and reduced food consumption (up to 12 % gestation days 8, 10, 19), 4/20: ulcers, thickened mucosa were observed. At 3300 mg/kg bw dose group, reduced body weight (up to 17 % below control) and decreased body weight change, reduced food consumption up to 65% each day, reduced gravid uterus weight by 22% (caused by lowered fetal weights) and 20/21: thickened mucosa, greyish discolored in 2/21; ulcers (also in the prematurely deceased dam) were observed. The number of early, late and total resorptions was increased in the 3300 mg/kg bw group. Moreover the ratio of viable fetuses to implantation sites was decreased compared to the controls. This was due to a total post-implantation loss of two dams in this dose group. A statistically significant reduction in fetal weights and number of viable fetuses as compared to the control was observed. At 3300 mg/kg bw dose group. No external, skeletal or soft tissue malformations and no external variations were seen in controls or in dosed groups. The fetal incidence of the skeletal variations was 5 in the controls and 8 (330 mg/kg bw), 13 (990 mg/kg bw) and 6 (3300 mg/kg bw) in the test group respectively. The finding in the 990 mg/kg bw group was judged as incidental as no dose-relationship was noted. The skeletal retardations (fetal incidence) were 129 in the controls and 137 (330 mg/kg bw), 130 (990 mg/kg bw) and 125 (3300 mg/kg bw) in the dosed groups. No dose-related soft tissue variations were observed, as seen in the following fetal incidences: 8 (control), 12 (330 mg/kg bw), 10 (990 mg/kg bw) and 9 (3300 mg/kg bw). Hence, the NOAEL for maternal toxicity was 95 mg/kg bw/day and the NOAEL for reproductive and developmental toxicity was >950 mg/kg bw/day as the post-implantation loss and decreased mean fetal body weight were considered to be secondary to maternal toxicity when female CD rats were treated with test chemical orally from day 5 - 19 of pregnancy.

Effect on developmental toxicity: via oral route
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
NOAEL
950 mg/kg bw/day
Study duration:
subchronic
Species:
rat
Quality of whole database:
Data is Klimicsh 2 and from authoritative database
Effect on developmental toxicity: via inhalation route
Endpoint conclusion:
no study available
Effect on developmental toxicity: via dermal route
Endpoint conclusion:
no study available
Additional information

Data available for the read across chemicals was reviewed to determine the developmental toxicity of test chemical. The studies are as mentioned below:

Study 1:

The prenatal developmental toxicity study following OECD guideline 414 was performed on female CD rats. Test material was soluble in water (aqua ad iniectabilia). Dose concentration were prepared at 0, 330, 990 or 3300 mg/kg-day (corresponding to 0, 95, 286, and 950 mg/kg-day active substance, respectively) and administered in a dose volume of 10 ml/kg bw from day 5 to 19 of pregnancy once daily via gavage. 25 female rats /dose group were treated and 20 pregnant animals were evaluated. 20 rats (0, 330, 990 mg/kg bw group) and 21 rats (3300 mg/kg bw group) were evaluated for maternal toxicity. 1 male and 1 female were placed in one cage during the dark period. Mating was repeated until vaginal smear showed presence of sperm. All animals were observed for clinical signs, Body weight and food consumption daily. Also number of fetuses alive, Weight of fetuses, sex distribution of fetuses, skeletal anomalies (50 %) and soft tissue anomalies (50 %) were noted. One dam at 3300 mg/kg day died on gestation day 15 and in same dose group 13/21 abdominal position, 2/21: pilo-erection, reduced motility was noted. At≥990 mg/kg bw dose group, reduction of the net weight change (carcass weight minus day 6 body weight) from day 6 onwards (23% and 67%) and reduced food consumption (up to 12 % gestation days 8, 10, 19), 4/20: ulcers, thickened mucosa were observed. At 3300 mg/kg bw dose group, reduced body weight (up to 17 % below control) and decreased body weight change, reduced food consumption up to 65% each day, reduced gravid uterus weight by 22% (caused by lowered fetal weights) and 20/21: thickened mucosa, greyish discolored in 2/21; ulcers (also in the prematurely deceased dam) were observed. The number of early, late and total resorptions was increased in the 3300 mg/kg bw group. Moreover the ratio of viable fetuses to implantation sites was decreased compared to the controls. This was due to a total post-implantation loss of two dams in this dose group. A statistically significant reduction in fetal weights and number of viable fetuses as compared to the control was observed. At 3300 mg/kg bw dose group. No external, skeletal or soft tissue malformations and no external variations were seen in controls or in dosed groups. The fetal incidence of the skeletal variations was 5 in the controls and 8 (330 mg/kg bw), 13 (990 mg/kg bw) and 6 (3300 mg/kg bw) in the test group respectively. The finding in the 990 mg/kg bw group was judged as incidental as no dose-relationship was noted. The skeletal retardations (fetal incidence) were 129 in the controls and 137 (330 mg/kg bw), 130 (990 mg/kg bw) and 125 (3300 mg/kg bw) in the dosed groups. No dose-related soft tissue variations were observed, as seen in the following fetal incidences: 8 (control), 12 (330 mg/kg bw), 10 (990 mg/kg bw) and 9 (3300 mg/kg bw). Hence, the NOAEL for maternal toxicity was 95 mg/kg bw/day and the NOAEL for reproductive and developmental toxicity was >950 mg/kg bw/day as the post-implantation loss and decreased mean fetal body weight were considered to be secondary to maternal toxicity when female CD rats were treated with test chemical orally from day 5 - 19 of pregnancy.

 

Study 2: The developmental toxicity study of test chemical was performed on female pregnant rats. The test material was administered in dose concentration 0, 30, 90 or 300 mg/kg bw on days 6 through 17 of gestation via gavage. Clinical signs, gestational body weights, food consumption, gravid uterine weight, total number of corpora lutea, implantation, early and late resorptions, were noted in dams while live and dead fetuses, sex, individual body weights of fetuses, visceral (50 %) and skeletal (50 %) abnormalities were observed in fetuses. No treatment-related effects on the incidence of fetal external, visceral, or skeletal malformations or developmental variations were observed among litters from dams in any of the treated groups. Hence the maternal and developmental no-observed-effect level (NOEL) was considered to be 300 mg/kg bw/d, the highest level, when female rats were treated with test chemical orally on days 6 through 17 of gestation.

 

Study 3: In a developmental toxicity reproductive toxicity was evaluated in Sprague-Dawley female rats by using test chemical in the concentration of 0, 100, 300, or 1000 mg/kg/day orally by gavage in corn oil. No maternal mortality and clinical signs or behavioral changes were observed in treated female rats as compared to control. No effect on body weight and feed consumption changes were observed in treated female rats as compared to control. Similarly, no effect number of corpora lutea, number of live fetuses per litter, litter size, mean fetal body weight, or mean crown-rump length was observed in treated rats. Ratio of male and female pups at the 1000 mg/ kg/day dose level was significantly different from the control group but was not considered treatment related. Slight but significant increase in relative liver weight of treated female rats was observed as compared to control. In addition, No developmental parameter such as viability, fetal body weight and external malformations were observed in treated fetuses as compared to control. One fetus with bent limb bones, two fetuses from different mothers with microphthalmia and two other fetuses with omphalocele were observed at 1000 mg/kg/day and single fetus with multiple malformations were observed at 300 mg/kg/day in treated fetuses as compared to control. The incidence of developmental variations in the treated litters was not significantly increased over the control incidence. They occurred in low frequency and were distributed randomly across the test chemical treated and control groups. Therefore, NOAEL was considered to be 300 mg/kg bw for P generation and 1000 mg/kg for F1 generation when Sprague-Dawley female rats were treated with test chemical orally by gavage from day 6 to 15 of gestation.

Based on the data available from different studies, test chemical did not showed developmental toxicity at dose concentration between 300- 1000mg/kg bw/day. Hence the test chemical is not likely to classify as a reproductive and developmental toxicant as per the criteria mentioned in CLP regulation.

Justification for classification or non-classification

Thus, comparing this value with the criteria of CLP regulation, the test chemical is not likely to classify as reproductive and developmental toxicant.

Additional information